Pressmeddelanden från QLife

Qlife announces that two investors have entered agreements to subscribe for shares if the rights issue is subscribed below approx. 51.0 percent, taking over commitments from a group of guarantors

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 27 feb 18:20

Qlife announces that two investors have entered agreements to subscribe for shares if the rights issue is subscribed below approx. 51.0 percent, taking over commitments from a group of guarantors

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 27 feb 18:20

Kommuniké från extra bolagsstämma 2026 i Qlife Holding AB

Qlife Holding AB (”Bolaget” eller ”Qlife”) höll den 26 februari 2026 extra bolagsstämma varvid i huvudsak följande beslut fattades.

Cision • 26 feb 11:05

Bulletin from Extraordinary General Meeting 2026 of Qlife Holding AB

Qlife Holding AB (the “Company” or “Qlife”) held an Extraordinary General Meeting on 26 February 2026, at which the following resolutions we...

Cision • 26 feb 11:05

Qlife launches pharmacy pilot project in Nordic markets

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, today announces that the previously communicated ...

Cision • 25 feb 08:30

Qlife launches pharmacy pilot project in Nordic markets

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, today announces that the previously communicated ...

Cision • 25 feb 08:30

Guarantor converts guarantee commitment of SEK 0.5 million into binding subscription commitment and top guarantor waives guarantee compensation in Qlife’s ongoing rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 19 feb 18:03

Guarantor converts guarantee commitment of SEK 0.5 million into binding subscription commitment and top guarantor waives guarantee compensation in Qlife’s ongoing rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 19 feb 18:03

QLIFE HOLDING AB, Interim Report Q4, October - December 2025

Positioned for scale in 2026 The full report is attached and can also be found here: https://qlifeholding.

Cision • 11 feb 08:30

QLIFE HOLDING AB, Interim Report Q4, October - December 2025

Positioned for scale in 2026 The full report is attached and can also be found here: https://qlifeholding.

Cision • 11 feb 08:30

Kallelse till extra bolagsstämma 2026 i Qlife Holding AB

Cision • 26 jan 10:56

Notice of Extraordinary General Meeting 2026 in Qlife Holding AB

Cision • 26 jan 10:56

Qlife submits Egoo PHE home testing system for regulatory approval

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, today announces that the Company has formally sub...

Cision • 26 jan 08:30

Qlife submits Egoo PHE home testing system for regulatory approval

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, today announces that the Company has formally sub...

Cision • 26 jan 08:30

Qlife resolves on a partially guaranteed rights issue of approx. SEK 31.4 million and proposes an over-allotment option, enters bridge loan agreements and postpones the exercise period of warrants TO7

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 22 jan 20:50

Qlife resolves on a partially guaranteed rights issue of approx. SEK 31.4 million and proposes an over-allotment option, enters bridge loan agreements and postpones the exercise period of warrants TO7

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 22 jan 20:50

Qlife prepares for pharmacy testing in Nordic markets

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, is preparing a pilot project for blood testing in...

Cision • 19 jan 08:30

Qlife prepares for pharmacy testing in Nordic markets

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, is preparing a pilot project for blood testing in...

Cision • 19 jan 08:30

Egoo Health achieves breakthrough precision in key diabetes biomarker test, paving the way for partnerships

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, together with its partner Hipro Biotechnology Co.

Cision • 15 jan 08:30

Egoo Health achieves breakthrough precision in key diabetes biomarker test, paving the way for partnerships

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, together with its partner Hipro Biotechnology Co.

Cision • 15 jan 08:30

Qlife provides end-year operational update on key issues

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, provides a year-end operational update on key iss...

Cision • 23 dec 2025 08:30

Qlife provides end-year operational update on key issues

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, provides a year-end operational update on key iss...

Cision • 23 dec 2025 08:30

Qlife and Hipro sign exclusive commercial agreement covering Qlife’s sale of Hipro products in EU and US markets

Qlife Holding AB ("Qlife" or the "Company"), a first mover in clinical-grade home diagnostics, today announced that it has entered into an e...

Cision • 16 dec 2025 08:31

Qlife and Hipro sign exclusive commercial agreement covering Qlife’s sale of Hipro products in EU and US markets

Qlife Holding AB ("Qlife" or the "Company"), a first mover in clinical-grade home diagnostics, today announced that it has entered into an e...

Cision • 16 dec 2025 08:31

The Letter of Intent with Hipro Biotechnology regarding the reverse takeover has been extended until 31 December 2026 and the valuation term will re-evaluated once a structure has been established

Qlife Holding AB ("Qlife" or the "Company") announces an extension of the non-binding Letter of Intent regarding the potential reverse takeo...

Cision • 16 dec 2025 08:30

The Letter of Intent with Hipro Biotechnology regarding the reverse takeover has been extended until 31 December 2026 and the valuation term will re-evaluated once a structure has been established

Qlife Holding AB ("Qlife" or the "Company") announces an extension of the non-binding Letter of Intent regarding the potential reverse takeo...

Cision • 16 dec 2025 08:30

Egoo Health powers AI-driven personalized diabetes management in China

Qlife Holding AB ("Qlife" or the "Company") is proud to announce that its Egoo Health blood testing platform will play a central role in a g...

Cision • 12 dec 2025 08:30

Egoo Health powers AI-driven personalized diabetes management in China

Qlife Holding AB ("Qlife" or the "Company") is proud to announce that its Egoo Health blood testing platform will play a central role in a g...

Cision • 12 dec 2025 08:30

Qlife’s Birmingham PKU clinical trial published with strong results – key milestone toward CE-mark submission and market launch

Qlife Holding AB (“Qlife” or the “Company”) a first mover in clinical-grade home diagnostics, announces publication of the clinical study fo...

Cision • 05 dec 2025 11:13

Qlife’s Birmingham PKU clinical trial published with strong results – key milestone toward CE-mark submission and market launch

Qlife Holding AB (“Qlife” or the “Company”) a first mover in clinical-grade home diagnostics, announces publication of the clinical study fo...

Cision • 05 dec 2025 11:13

Update on the reverse takeover process – “Red Chip” structure will not be approved by Nasdaq – other structures are pursued

Qlife Holding AB (“Qlife” or “the Company”) and Hipro Biotechnology Co.

Cision • 14 nov 2025 17:37

Update on the reverse takeover process – “Red Chip” structure will not be approved by Nasdaq – other structures are pursued

Qlife Holding AB (“Qlife” or “the Company”) and Hipro Biotechnology Co.

Cision • 14 nov 2025 17:37

QLIFE HOLDING AB, Interim Report Q3, July - September 2025

Advancing Integration & Innovation: Building a Diagnostics Powerhouse

Cision • 12 nov 2025 08:30

QLIFE HOLDING AB, Interim Report Q3, July - September 2025

Advancing Integration & Innovation: Building a Diagnostics Powerhouse

Cision • 12 nov 2025 08:30

The Letter of Intent with Hipro Biotechnology Co., Ltd. regarding reverse takeover has been extended

Qlife Holding AB ("Qlife" or the "Company”) announces an extension of the Letter of Intent regarding a potential reverse takeover (the “Tran...

Cision • 05 okt 2025 17:00

The Letter of Intent with Hipro Biotechnology Co., Ltd. regarding reverse takeover has been extended

Qlife Holding AB ("Qlife" or the "Company”) announces an extension of the Letter of Intent regarding a potential reverse takeover (the “Tran...

Cision • 05 okt 2025 17:00

Qlife Holding AB announces the outcome of the exercise of warrants series TO 6

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALA...

Cision • 22 sep 2025 18:00

Qlife Holding AB announces the outcome of the exercise of warrants series TO 6

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALA...

Cision • 22 sep 2025 18:00

Qlife announces additional product line and progresses two new tests into clinical trials

Qlife, a first mover in clinical-grade home diagnostics, and its partner Hipro Biotechnology are advancing two additional biomarker tests—nt...

Cision • 15 sep 2025 08:30

Qlife announces additional product line and progresses two new tests into clinical trials

Qlife, a first mover in clinical-grade home diagnostics, and its partner Hipro Biotechnology are advancing two additional biomarker tests—nt...

Cision • 15 sep 2025 08:30

QLIFE HOLDING AB, Interim Report Q2, April to June 2025

Towards a merger with a vision

Cision • 27 aug 2025 08:30

QLIFE HOLDING AB, Interim Report Q2, April to June 2025

Towards a merger with a vision

Cision • 27 aug 2025 08:30

Progress update on the reverse takeover process between Qlife and Hipro

Gothenburg, Sweden - Qlife Holding AB (“Qlife” or the “Company”) and Hipro Biotechnology Co.

Cision • 27 aug 2025 08:00

Progress update on the reverse takeover process between Qlife and Hipro

Gothenburg, Sweden - Qlife Holding AB (“Qlife” or the “Company”) and Hipro Biotechnology Co.

Cision • 27 aug 2025 08:00

Qlife Holding AB increases existing credit facility and extends the maturity date

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALA...

Cision • 21 aug 2025 18:22

Qlife Holding AB increases existing credit facility and extends the maturity date

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALA...

Cision • 21 aug 2025 18:22

Qlife together with Birmingham Women’s and Children’s NHS Foundation Trust achieve positive results for its rare disease self-test PHE product

Gothenburg, Sweden - Qlife Holding AB (“Qlife” or the “Company”) announces that it has finalized its clinical study for children and young p...

Cision • 21 aug 2025 09:13

Qlife together with Birmingham Women’s and Children’s NHS Foundation Trust achieve positive results for its rare disease self-test PHE product

Gothenburg, Sweden - Qlife Holding AB (“Qlife” or the “Company”) announces that it has finalized its clinical study for children and young p...

Cision • 21 aug 2025 09:13

Qlife together with Birmingham Women’s and Children’s NHS Foundation Trust achieve positive results for its rare disease self-test PHE product

Gothenburg, Sweden - Qlife Holding AB (“Qlife” or the “Company”) announces that it has finalized its clinical study for children and young p...

Cision • 21 aug 2025 08:30

Qlife together with Birmingham Women’s and Children’s NHS Foundation Trust achieve positive results for its rare disease self-test PHE product

Gothenburg, Sweden - Qlife Holding AB (“Qlife” or the “Company”) announces that it has finalized its clinical study for children and young p...

Cision • 21 aug 2025 08:30

Qlife resolves to carry out a directed set-off issue of approximately SEK 2.47 million in accordance with previously announced credit facility agreement

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALA...

Cision • 09 jul 2025 22:09

Qlife resolves to carry out a directed set-off issue of approximately SEK 2.47 million in accordance with previously announced credit facility agreement

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALA...

Cision • 09 jul 2025 22:09

Qlife enters letter of intent with Hipro Biotechnology Co., Ltd. to join forces through a reverse takeover

Qlife Holding AB ("Qlife" or the "Company") has entered into a non-binding letter of intent ("Letter of Intent") with Hipro Biotechnology Co...

Cision • 05 jun 2025 08:00

Qlife enters letter of intent with Hipro Biotechnology Co., Ltd. to join forces through a reverse takeover

Qlife Holding AB ("Qlife" or the "Company") has entered into a non-binding letter of intent ("Letter of Intent") with Hipro Biotechnology Co...

Cision • 05 jun 2025 08:00

Kommuniké från årsstämma 2025 i Qlife Holding AB

Qlife Holding AB höll den 28 maj 2025 årsstämma varvid i huvudsak följande beslut fattades.

Cision • 28 maj 2025 12:18

Bulletin from the annual general meeting 2025 of Qlife Holding AB

Qlife Holding AB held its annual general meeting on 28 May 2025.

Cision • 28 maj 2025 12:18

QLIFE HOLDING AB, Interim Report Q1, January to March 2025

Progress on all levels

Cision • 20 maj 2025 08:30

QLIFE HOLDING AB, Interim Report Q1, January to March 2025

Progress on all levels

Cision • 20 maj 2025 08:30

Qlife Holding AB publishes Annual Report for 2024

Qlife Holding AB's ("Qlife") Annual Report is available on Qlife's website: https://qlifeholding.

Cision • 07 maj 2025 09:01

Qlife Holding AB publicerar årsredovisning för 2024

Qlife Holding AB:s (“Qlife”) årsredovisning finns från och med idag tillgänglig på Qlifes hemsida: https://qlifeholding.

Cision • 07 maj 2025 09:01

Kallelse till årsstämma 2025 i Qlife Holding AB

Aktieägarna i Qlife Holding AB, org.nr 559224-8040, kallas till årsstämma den 28 maj 2025 kl.

Cision • 25 apr 2025 11:26

Kallelse till årsstämma 2025 i Qlife Holding AB

Aktieägarna i Qlife Holding AB, org.nr 559224-8040, kallas till årsstämma den 28 maj 2025 kl.

Cision • 25 apr 2025 11:26

Qlife announces strategic roadmap update

Qlife is positioned at the forefront of the fast-growing at-home diagnostics market, offering lab-grade biomarker testing with global potent...

Cision • 10 apr 2025 13:00

Qlife announces strategic roadmap update

Qlife is positioned at the forefront of the fast-growing at-home diagnostics market, offering lab-grade biomarker testing with global potent...

Cision • 10 apr 2025 13:00

Qlife announces that it has received approval from UK authorities to initiate a clinical trial in the UK

The Egoo Phe System, developed to measure phenylalanine (Phe) levels associated with the PKU condition, is now entering its final phase ahea...

Cision • 25 mar 2025 09:00

Qlife announces that it has received approval from UK authorities to initiate a clinical trial in the UK

The Egoo Phe System, developed to measure phenylalanine (Phe) levels associated with the PKU condition, is now entering its final phase ahea...

Cision • 25 mar 2025 09:00

Bulletin from the extraordinary general meeting in Qlife Holding AB on 21 March 2025

Today, on 21 March 2025, an extraordinary general meeting was held in Qlife Holding AB.

Cision • 21 mar 2025 10:32

Kommuniké från extra bolagsstämma i Qlife Holding AB den 21 mars 2025

Idag, den 21 mars 2025, hölls extra bolagsstämma i Qlife Holding AB.

Cision • 21 mar 2025 10:32

Qlife announces the last day of trading in BTA

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 14 mar 2025 17:45

Qlife announces the last day of trading in BTA

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 14 mar 2025 17:45

Qlife carries out a directed issue to guarantors in connection with the completed rights issue and a directed issue of warrants to JEQ Capital AB

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 05 mar 2025 11:31

Qlife carries out a directed issue to guarantors in connection with the completed rights issue and a directed issue of warrants to JEQ Capital AB

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 05 mar 2025 11:31

Qlife reaffirms its strategy and plans to expand the Board with three new members

Following a successful rights issue, Qlife has convened an extraordinary general meeting to expand its Board of Directors with three new mem...

Cision • 04 mar 2025 10:45

Qlife reaffirms its strategy and plans to expand the Board with three new members

Following a successful rights issue, Qlife has convened an extraordinary general meeting to expand its Board of Directors with three new mem...

Cision • 04 mar 2025 10:45

Notice of Extraordinary General Meeting 2025 in Qlife Holding AB

Qlife Holding AB, reg.no. 559224-8040 (the ”Company”), will hold an Extraordinary General Meeting on 21 March 2025 at.

Cision • 04 mar 2025 10:40

Kallelse till extra bolagsstämma i Qlife Holding AB

Aktieägarna i Qlife Holding AB, org.nr 559224-8040 (”Bolaget”), kallas till extra bolagsstämma, den 21 mars 2025 kl.

Cision • 04 mar 2025 10:40

Qlife announces outcome in rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 26 feb 2025 19:27

Qlife announces outcome in rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 26 feb 2025 19:27

The subscription period in Qlife’s rights issue ends on Tuesday, 25 February 2025

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 21 feb 2025 10:00

The subscription period in Qlife’s rights issue ends on Tuesday, 25 February 2025

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 21 feb 2025 10:00

Qlife has successfully verified the biomarkers related to the previously announced LOI

Qlife is pleased to announce that, in collaboration with Hipro Biotechnology, the company has successfully verified biomarkers related to th...

Cision • 21 feb 2025 09:00

Qlife has successfully verified the biomarkers related to the previously announced LOI

Qlife is pleased to announce that, in collaboration with Hipro Biotechnology, the company has successfully verified biomarkers related to th...

Cision • 21 feb 2025 09:00

Qlife announces the launch of Egoo.AI and the start of sales for the Women’s Health platform

Qlife is proud to announce a major expansion of Egoo.

Cision • 17 feb 2025 09:00

Qlife announces the launch of Egoo.AI and the start of sales for the Women’s Health platform

Qlife is proud to announce a major expansion of Egoo.

Cision • 17 feb 2025 09:00

Qlife launches Thyroid Disease and Vitamin D biomarkers, now available for immediate sales

Qlife is proud to announce the expansion of the Egoo.

Cision • 14 feb 2025 09:00

Qlife launches Thyroid Disease and Vitamin D biomarkers, now available for immediate sales

Qlife is proud to announce the expansion of the Egoo.

Cision • 14 feb 2025 09:00

Members of the Board of Directors and management intend to subscribe in the ongoing rights issue

Qlife Holding AB (publ) (“Qlife” or the “Company”) announces that members of the Company's Board of Directors and management, including CEO ...

Cision • 12 feb 2025 08:00

Members of the Board of Directors and management intend to subscribe in the ongoing rights issue

Qlife Holding AB (publ) (“Qlife” or the “Company”) announces that members of the Company's Board of Directors and management, including CEO ...

Cision • 12 feb 2025 08:00

The subscription period in Qlife’s rights issue begins today

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 11 feb 2025 08:00

The subscription period in Qlife’s rights issue begins today

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 11 feb 2025 08:00

Qlife publishes information memorandum due to upcoming rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 10 feb 2025 14:00

Qlife publishes information memorandum due to upcoming rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 10 feb 2025 14:00

QLIFE HOLDING AB, Interim Report Q4, October to December 2024

Transition to a commercial business

Cision • 06 feb 2025 09:00

QLIFE HOLDING AB, Interim Report Q4, October to December 2024

Transition to a commercial business

Cision • 06 feb 2025 09:00

Qlife comments on the CEO of the company getting a sanction from Finansinspektionen

The CEO of Qlife Thomas Warthoe has been sanctioned by Finansinspektionen related to insider information.

Cision • 31 jan 2025 20:34

Qlife comments on the CEO of the company getting a sanction from Finansinspektionen

The CEO of Qlife Thomas Warthoe has been sanctioned by Finansinspektionen related to insider information.

Cision • 31 jan 2025 20:34

Qlife carries out a rights issue of approximately SEK 11.8 million and enters into an agreement for a credit facility of SEK 5.6 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 29 jan 2025 07:59

Qlife carries out a rights issue of approximately SEK 11.8 million and enters into an agreement for a credit facility of SEK 5.6 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Cision • 29 jan 2025 07:59

Qlife has signed a letter of intent with a top-20 global Pharma company to explore a potential commercial collaboration

Qlife has been in discussions with a top-20 global Pharma company to explore opportunities for the sales, distribution, and marketing of the...

Cision • 28 jan 2025 09:00

Qlife has signed a letter of intent with a top-20 global Pharma company to explore a potential commercial collaboration

Qlife has been in discussions with a top-20 global Pharma company to explore opportunities for the sales, distribution, and marketing of the...

Cision • 28 jan 2025 09:00